

**Filed On Behalf Of:**

Alnylam Pharmaceuticals, Inc.

**By:**

Scott K. Reed  
sreed@venable.com  
212-218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ALNYLAM PHARMACEUTICALS, INC.,  
Petitioner,  
v.  
SILENCE THERAPEUTICS GMBH,  
Patent Owner.

---

Case PGR2018-00089  
U.S. Patent No. 9,790,501

---

**PETITIONER'S UPDATED MANDATORY NOTICE**

Petitioner Alnylam Pharmaceuticals, Inc. (“Petitioner”) hereby files its updated mandatory notice pursuant to 37 C.F.R. § 42.8(a)(3).

**A. Lead and Backup Counsel (37 C.F.R. § 42.8(b)(3))**

Petitioner reports a change of firm name for lead and back-up counsel from Fitzpatrick, Cella, Harper & Scinto to Venable LLP. Updated information for lead and back-up counsel is included below:

| <b>Lead Counsel</b>                                                                                                                                  | <b>Back-Up Counsel</b>                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Scott K. Reed (Reg. No. 32,433)<br>sreed@venable.com<br>Venable LLP<br>1290 Avenue of the Americas<br>New York, NY 10104-3800<br>Tel: (212) 218-2100 | Prajakta A. Sonalker (Reg. No. 65,406)<br>psonalker@venable.com<br>Venable LLP<br>1290 Avenue of the Americas<br>New York, NY 10104-3800<br>Tel: (212) 218-2100 |

**B. Service Information (37 C.F.R. § 42.8(b)(4))**

Updated contact information for lead and back-up counsel is included above. Please address all correspondence to the lead and back-up counsel at the above addresses. Petitioner also consents to electronic service to AlnylamPTAB@venable.com and to the email addresses above.

**C. Related Matters (37 C.F.R. § 42.8(b)(2))**

In accordance with the Office Patent Trial Practice Guide (77 Fed. Reg. 48,756, at 48,760 (Aug. 14, 2012)), Petitioner further identifies the following related matters:

- U.S. Patent Application No. 16/013,776 (“the ’776 application”), filed on June 20, 2018 and pending.
- U.S. Patent Application No. 16/122,827 (“the ’827 application”), filed on September 5, 2018 and pending (unpublished).

The pending ’776 and ’827 applications claim priority benefit of U.S. Patent Application No. 15/589,968, which issued as U.S. Patent No. 9,790,501. Petitioner notes that for the ’776 application, the examiner in an August 15, 2018 Non-Final Rejection rejected the pending claims to doubly-modified siRNA molecules for lack of written description and found that EP 02017601, EP 03008383, and Provisional App. No. 60/402,541, which the ’776 application claims priority to, fail to disclose doubly-modified siRNA molecules as claimed, in addition to rejections under 35 U.S.C. §§ 102 and 103 and for obviousness-type double-patenting.

Petitioner also notes an update in the related matter, PGR2018-00059, which involves related U.S. Patent No. 9,695,423. On October 10, 2018, the Patent Trial and Appeal Board (“Board”) issued a decision denying institution of post-grant review. On November 2, 2018, pursuant to 37 C.F.R. § 42.71(d), Petitioner filed a request for rehearing of the Board’s decision to not institute trial. *Alnylam Pharmaceuticals, Inc. v. Silence Therapeutics GMBH*, Case PGR2018-00059,

Paper 11 (P.T.A.B. November 2, 2018) (Petitioner's Request for Rehearing Under 37 C.F.R. § 42.71).

Dated: November 13, 2018

Respectfully submitted,

/s/ Scott K. Reed

Scott K. Reed (Reg. No. 32,433)  
Prajakta A. Sonalker (Reg. No. 65,406)  
VENABLE LLP  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel: (212) 218-2100

Counsel for Petitioner Alnylam  
Pharmaceuticals, Inc.

## **CERTIFICATE OF SERVICE**

The undersigned certifies that a copy of the foregoing **Petitioner's Updated Mandatory Notice** was served electronically via email on November 13, 2018 at the following addresses of record:

### **Lead Counsel**

Matthew Kreeger, Reg. No. 56,398  
MKreeger@mofo.com  
MORRISON & FOERSTER LLP  
425 Market Street  
San Francisco, CA 94105  
Tel: (415) 268-6467  
Fax: (415) 268-7522

### **Back-up Counsel**

Jian Xiao, Reg. No. 55,748  
JXiao@mofo.com  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, CA 94304  
Tel: (650) 813-5736  
Fax: 650) 494-0792

Patent Owner has consented to service by electronic mail to  
68013-501-PGR@mofo.com.

Dated: November 13, 2018

Respectfully submitted,

/s/ Scott K. Reed

Scott K. Reed (Reg. No. 32,433)  
VENABLE LLP  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel: (212) 218-2100